by mfantozzi | Nov 4, 2021 | 2021, Past Events, Scientific
Dario Neri, co-founder, CEO and CSO, is giving a presentation to address the question on how to achieve the therapeutic dose at the tumor site with cytokine-based targeted products. Roberto De Luca, Head of Antibody Therapeutics at Philogen, is also giving a...by last | Nov 3, 2021 | 2021, Past Events
Dario Neri, co-founder, CEO and CSO, is giving a presentation focused on Tripokin, a novel fusion protein capable of an exceptionally selective uptake at the tumor site. The product contains two highly synergistic cytokine moieties (interleukin-2 and tumor necrosis...by last | Oct 20, 2021 | 2021, Past Events
Listen to Webcastby mfantozzi | Oct 15, 2021 | 2021, Press Releases, Scientific
Philogen announces that Philochem’s European Patent 3083957 relating to important features of proprietary DNA-encoded chemical libraries (“ESAC 2+1” technology) was upheld after Oral Proceedings in front of the Opposition Division at the European Patent Office. Read...by last | Oct 5, 2021 | 2021, Past Events
Philogen participates at the BIO-Europe Digital 2021 BIO-Europe (informaconnect.com) – 2021, the international partnering event in the life science and pharma industry, on October 25-28, 2021 Please meet with us in case you are interested in a collaboration or...by mfantozzi | Sep 29, 2021 | 2021, Press Releases, Scientific
Philogen provides corporate update